Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus

Climacteric

Volumn 5, Issue 3, 2002, Pages 286-292

  Araujo D A C ^a   Farias, M L F ^a   Andrade, A T L ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Hormone replacement therapy; Menopause; Type 2 diabetes mellitus

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESTROGEN THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036387845     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.3.286.292     Document Type: Article

References (24)

1. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996;23:209-16
2. Barrett-Connor E. The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas 1996;23:227-34
3. Investigaciones sobre la menopausia en los años noventa. Informe de un grupo científico da la OMS, Ginebra, Organización Mundial de la Salud, 1996. OMS, serie de informes técnicos, no. 866
4. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal estrogen and progestin use and the risks of cardiovascular disease. N Engl J Med 1997;335:453-61
5. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. Diabetes Care 1998;21:1589-95
6. Bush DE, Jones CE, Bass KM, et al. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998;104:552-8
7. Coope J. Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas 1996;23:159-68
8. Riechelson LS, Wahner HW, Melton LJ, et al. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311;1273-5
9. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97
10. Matheus DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
11. Walsh BW, Schiff I, Rosner L, et al. Effects of postmenopausal estrogen replacement and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204
12. Nabulsi AA, Folson AR, White A. Association of hormone-replacement therapy with various cardiovascular risks factors in postmenopausal women. N Engl J Med 1993;328:1069-75
13. Robinson JG, Folsom AR, Nabulsi AA, et al. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? Diabetes Care 1996;19:480-5
14. Li GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive menopausal women. J Hypertens 1994;8:491-4
15. Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995;49:87-90
16. O'Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1994; 80:1783-9
17. The Writing Group for the Postmenopausal Estrogen/Progestin Interventions trial. Effects of estrogen or estrogen-progestin regimes on heart disease risk factors in postmenopausal women. J Am Med Assoc 1996;273:199-208
18. Mosnier-Pudar H, Faguer B, Guyenne TT, et al. Effects of deprivation and replacement by percutaneous 17β-oestradiol and oral progesterone on blood pressure and metabolic parameters in menopause patients with non-insulin-dependent diabetes. Arch Mal Coeur Vaiss 1991;84:1111-15
19. Brussaard HE, Gevers Leuven JA, Kluft C, et al. Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Arterioscler Thromb Vasc Biol 1997;17:324-30
20. Sattar N, Jaap AJ, MacCuish AC. Hormone replacement therapy and cardiovascular risk in postmenopausal women with NIDDM. Diabetic Med 1996;13:782-8
21. Anderson B, Mattsson L, Hahn L, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:638-43
22. Samsioe G. Effects of estrogen in various lipids constituents. Consultant 1990;30:58-62
23. Walsh BW, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal oestrogen on HDL metabolism. J Lipid Res 1994;35:2083-93
24. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990;75:18S-25S